Overview

Update
Total Equity Funding
$104.5M in 4 Rounds from 5 Investors
Most Recent Funding
$50.6M Series B on September 23, 2014
Headquarters:
Seattle, WA
Description:
VentiRx Pharmaceuticals develops novel TLR8 therapeutics for the treatment of cancer, allergy, and respiratory and autoimmune diseases.
Founders:
,
Categories:
Therapeutics, Health Care, Biotechnology
Website:
http://www.ventirx.com
Social:

Company Details

Update

VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of medicines for the treatment of cancer, and respiratory and autoimmune diseases. The company focuses on the development of small molecule product candidates targeting toll-like receptor 8 (TLR8) agonists and antagonists. Its product pipeline comprises VTX-2337, a small molecule TLR8 agonist that stimulates myeloid dendritic cells and monocytes, and enhances natural killer cell responses for the treatment of solid tumors, ovarian and breast cancers, and NHL and SCHN; VTX-1463, a stand alone agent for the treatment of seasonal and perennial allergies; TLR8 antagonists for the treatment of autoimmune diseases; and multiple compounds that are treated as vaccine adjuvants. The company has a strategic agreement/collaboration with Celgene Corporation. VentiRx Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Seattle, Washington with operations in San Diego.

Funding Rounds (4) - $104.5M

Update
DateAmount / RoundValuationLead InvestorInvestors
Sep, 2014$50.6M / Series B5
Jan, 2010$25M / Series A4
Mar, 2007$26.6M / Series A3
2006$2.3M / Seed0

Current Team (11)

Update

Offices/Locations (1)

Update
  • Office

    1191 Second Avenue

    Suite 1105

    Seattle, WA 98101

    USA

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos